Aurobindo Pharma gets USFDA nod for its anti-epileptic drug

Drug firm Aurobindo Pharma has received final approval from the US health regulator for its Levetiracetam in Sodium Chloride injection used for treatment of seizures with epilepsy.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap Tech Control

Budget 2017

Presented By:

DAYS hours minutes
Presented by :

Co-Presenting Sponsor :

Associate Sponsors :

Co-Presenting Sponsor :

Associate Sponsors :

Home » News » Business

Jan 07, 2017, 05.23 PM | Source: PTI

Aurobindo Pharma gets USFDA nod for its anti-epileptic drug

Drug firm Aurobindo Pharma has received final approval from the US health regulator for its Levetiracetam in Sodium Chloride injection used for treatment of seizures with epilepsy.

Like this story, share it with millions of investors on M3

Aurobindo Pharma gets USFDA nod for its anti-epileptic drug

Drug firm Aurobindo Pharma has received final approval from the US health regulator for its Levetiracetam in Sodium Chloride injection used for treatment of seizures with epilepsy.

Post Your Comments

Share Cancel

| 1 Comments
Aurobindo Pharma gets USFDA nod for its anti-epileptic drug
Drug firm Aurobindo Pharma has received final approval from the US health regulator for its Levetiracetam in Sodium Chloride injection used for treatment of seizures with epilepsy.

The company "has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levetiracetam in Sodium Chloride injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) (single-use bags)," Aurobindo Pharma said in a filing to BSE.

The product is a generic version of HQ Specialty Pharma Corp's Levetiracetam in Sodium Chloride injection, it added.

"The product will be launched in Jan 2017," Aurobindo Pharma said.

Levetiracetam in Sodium Chloride injection is a CNS drug and indicated for partial onset seizures in adults (16 years and older) with epilepsy, myoclonic seizures in adults with juvenile myoclonic epilepsy, primary generalized tonic-clonic seizures in adults with idiopathic generalised epilepsy, it added.

"The approved product has an estimated market size of USD 32 million for the twelve months ending November 2016 according to IMS," Aurobindo Pharma said.

Aurobindo Pharna currently has a total of 304 Abbreviated New Drug Application (ANDA) approvals (263 final approvals including 16 from Aurolife Pharma LLC and 41 tentative approvals) from USFDA, it added.

Buy, Hold, Sell ? Hear it first on M3
Aurobindo Pharma gets USFDA nod for its anti-epileptic drug

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login